It is our ambition to contribute to global health by the delivery of better adjuvants to increase the success of vaccination campaigns in developed and developing countries. In pre-clinical studies with various types of antigens in large non-rodent species, our most advanced product gave significantly higher humoral responses than benchmark adjuvants after the first and second immunization.

Remarkably, a single injection with LiteVax Adjuvant gave similar and sometimes even higher antibody titers as two immunizations with benchmark adjuvant. So, it is a promising candidate for single-shot vaccines. The single-shot approach offers clear-cut benefits with respect to costs of vaccination (goods, logistics and staffing), time-to-immunity, complexity of vaccination campaigns and non-adherence. In developing countries with poor infrastructure, these are critical success factors of campaigns and better adjuvants play a decisive role. Furthermore, in emergency situations avoiding the need for a booster offers tremendous advantages.

The adjuvant is supplied as a ready-for-use product, which facilitates vaccine R&D and manufacturing. It is cheap, easy to manufacture, stable, filterable and ready-for-use in aqueous formulations. Pilot production has been completed successfully and manufacturing outline has been established. Test material is available for research purposes under a material transfer agreement. Please contact Luuk Hilgers at LUUK.HILGERS@LITEVAX.COM.